Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 77

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

Synnott, Naoise C., O’Connell, David, Crown, John, Duffy, Michael J.·2020·Breast Cancer Research and Treatment

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10549-019-05435-1

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 28

  1. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van’t Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA et al (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158:929–1044 · DOI · Paper page
  2. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L (2013) Mutational landscape and significance across 12 major cancer types. Nature 502:333–339 · DOI · Paper page
  3. Stephens PJ, Tarpey PS, Davies H, Van-Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerød A, Lee MT, Shen CY, Tee BT, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van’t Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SA, Salomon AV, Børresen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, Stratton MR, Oslo Breast Cancer Consortium (OSBREAC) (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400–404 · DOI · Paper page
  4. Network Cancer Genome Atlas (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70 · DOI · Paper page
  5. Pareja F, Geyer FC, Marchiò C, Burke KA, Weigelt B, Reis-Filho JS (2016) Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2:16036 · DOI · Paper page
  6. Duffy MJ, Synnott NC, Crown J (2017) Mutant p53 as a target for cancer treatment. Eur J Cancer 83:258–265 · DOI · Paper page
  7. Zhao D, Tahaney WM, Mazumdar A, Savage MI, Brown PH (2017) Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci 74:4171–4187 · DOI
  8. Salim KY, Maleki Vareki S, Danter WR, Koropatnick J (2016) COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget 7:41363–41379 · DOI · Paper page
  9. Maleki Vareki S, Salim KY, Danter WR, Koropatnick J (2018) Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. PLoS ONE 13:e0191766 · DOI
  10. Salim K, Maleki Vareki S, Danter W, Koropatnick J (2016) COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3 K/AKT/mTOR pathway. Eur J Cancer 69:S19 · DOI
  11. Lindemann A, Patel AA, Silver NL, Tang L, Liu Z, Wang L, Tanaka N, Rao X, Takahashi H, Maduka NK, Zhao M, Chen TC, Liu W, Gao M, Wang J, Frank SJ, Hittelman WN, Mills GB, Myers JN, Osman AA (2019) COTI-2, A novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-19-0096 · DOI · Paper page
  12. Ho RT, Salim KY, Lindemann A, Patel AM, Takahashi H, Wang L, Zhao M, Frank SJ, Myers J, Osman A, Lynam C, Silva AD (2018) COTI-2, a potent orally available small molecule targeting mutant p53, with promising efficacy as monotherapy and combination treatment in preclinical tumor models. J Clin Oncol 36:6040 · doi:10.1200/jco.2018.36.15_suppl.6040
  13. Westin SN, Nieves-Neira W, Lynam C, Salim KY, Silva AD, Ho R, Mills GB, Coleman RL, Janku F, Matei D (2018) Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer. In: Proceedings of the American Association for Cancer Research. http://www.abstractsonline.com/pp8/#!/4562/presentation/11184 · doi:10.1158/1538-7445.am2018-ct033
  14. Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9:176–198 · DOI · Paper page
  15. Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O’Donovan N et al (2017) Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer 140(1):234–246 · DOI
  16. Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O’Donovan N et al (2018) Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett 414:99–106 · DOI
  17. Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR (2005) Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem 280:16030–16037 · DOI · Paper page
  18. Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A (2018) How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ 25:104–113 · DOI · Paper page
  19. Green JA, Von Euler M, Abrahmsen LB (2018) Restoration of conformation of mutant p53. Ann Oncol 29:1325–1328 · DOI · Paper page
  20. Bauer MR, Joerger AC, Fersht AR (2016) 2-Sulfonylpyrimidines: mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci USA 113(36):E5271–E5280 · DOI
  21. Gogna R, Madan E, Kuppusamy P, Pati U (2012) Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modifications. Cell Death Dis 3:e286 · DOI
  22. Milner J, Watson JV (1990) Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein. Oncogene 5:1683–1690
  23. Rich RL, Hoth LR, Geoghegan KF, Brown TA, LeMotte PK, Simons SP, Hensley P, Myszka DG (2002) Kinetic analysis of estrogen receptor/ligand interactions. Proc Natl Acad Sci USA 99:8562–8567 · doi:10.1073/pnas.142288199
  24. Fabian C, Tilzer L, Sternson L (1981) Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos 2:381–390 · DOI
  25. Wang S, Konorev E, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B (2004) Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. J Biol Chem 279:25535–25543 · DOI · Paper page
  26. Kumar A, Palakurthi S (2013) P53 Gene therapy sensitizes resistant breast cancer cells to doxorubicin chemotherapy. Drug Deliv Lett 3:165–174 · doi:10.2174/2210303111303030002
  27. Anelli A (2003) Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Ann Oncol 14:428–432 · doi:10.1093/annonc/mdg104
  28. Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 22(321):288–300 · DOI · Paper page

Cited by

See all 77

Metadata

Authors
Synnott, N. C., O’Connell, D., Crown, J., & Duffy, M. J.
Venue
Breast Cancer Research and Treatment
Published
2019-09-19
Volume
179
Issue
1
Pages
47-56
ISSN
  • 0167-6806
  • 1573-7217
Cited by
77
References
10
Language
en
Licence
Funders
  • Irish Cancer Society (CCRC13GAL)
  • Cancer Clinical Research Trust

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. https://app.cochat.ai/papers/10.1007/s10549-019-05435-1
The paper
Synnott, N. C., O’Connell, D., Crown, J., & Duffy, M. J. (2020). COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-019-05435-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.